TGA says product information for some diabetes and weight loss drugs updated with warning of NAION disorder
Get our breaking news email, free app or daily news podcast
Australia’s medicines regulator has issued warnings for several type 2 diabetes and obesity-related treatments – including Ozempic and Mounjaro – over the potential to cause a “rare but severe” eye disorder that could lead to blindness.
The Therapeutic Goods Administration’s (TGA) warning came after several GLP-1 RA medicines marketed in Australia as Ozempic, Wegovy and Mounjaro, among other products, were linked to 36 cases of the condition.
Continue reading...This article was originally published by The Guardian and written by Achol Arok.
Read original article on The Guardian